Literature DB >> 11140884

Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients.

A Fukuda1, H Kobayashi, K Teramura, S Yoshimoto, N Ohsawa.   

Abstract

Granulocytopenia is commonly observed in interferon-alpha (IFN-alpha) therapy. Granulocyte colony-stimulating factor (G-CSF) has been identified as a primary cytokine that regulates neutrophil production, but the kinetics of G-CSF in IFN-alpha-induced granulocytopenia remains unclear. We investigated the effects of IFN-alpha on serum G-CSF levels and peripheral neutrophil counts (NC) in 15 chronic hepatitis C patients treated with standard-dose (10 MU) recombinant IFN-alpha for 24 weeks by using a chemiluminescent enzyme immunoassay for G-CSF. The time course of change after a single IFN-alpha injection showed that mean serum G-CSF levels and NC increased significantly compared with pretreatment values (p < 0.05), and were statistically correlated (r = 0.914, p = 0.0015). On repeating IFN-alpha administration, this change gradually became unclear, and granulocytopenia occurred, accompanied by a significant increase in serum G-CSF (p < 0.01). Both values reached a plateau within 2 weeks after starting treatment, and recovered rapidly after the cessation of therapy. Although continuous administration of IFN-alpha caused a time-dependent granulocytopenia, our results suggest that a single injection of IFN-alpha would be a potent inducer of G-CSF and NC in vivo as a short-term effect and that there would be negative-feedback regulation between them during long-term IFN-alpha therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140884     DOI: 10.1080/mccm.6.3.149.154

Source DB:  PubMed          Journal:  Cytokines Cell Mol Ther        ISSN: 1368-4736


  6 in total

1.  Interferon-based therapy for chronic hepatitis C: current and future perspectives.

Authors:  Valli De Re
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

2.  Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.

Authors:  Jian Wang; Gui-Ju Xiang; Bing-Xiang Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients.

Authors:  Fazal A Danish; Salman S Koul; Fazal R Subhani; Ahemd E Rabbani; Saeeda Yasmin
Journal:  Saudi J Gastroenterol       Date:  2008-07       Impact factor: 2.485

4.  Management of Hepatitis C Antiviral Therapy Adverse Effects.

Authors:  Hubert Sung; Michael Chang; Sammy Saab
Journal:  Curr Hepat Rep       Date:  2010-12-24

5.  Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.

Authors:  Glenn Wagner; Karen Chan Osilla; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Laveeza Bhatti; Matthew Bidwell Goetz; Mallory Witt
Journal:  AIDS Res Treat       Date:  2011-10-26

6.  Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.

Authors:  Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.